Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-77 (cancelled).

78. (currently amended) A method for luminal substance delivery, said method comprising:

providing a luminal prosthesis incorporating and/or coupled to a ~~the~~ substance, wherein the prosthesis comprises a rate limiting barrier; and

implanting the prosthesis in a body lumen so that the substance is released from the prosthesis at multiple rates including an initial rate and at least one subsequent rate which is substantially higher than the initial rate and begins after an appreciable preselected time period.

79. (original) A method as in claim 78, wherein the barrier has a sufficient thickness to allow diffusion of the substance through the barrier.

Claims 80-101 (cancelled).

102. (previously presented) A method as in any of claims 78-79, wherein the at least one subsequent rate begins within a time period ranging from 4 hours to 24 weeks in a vascular environment.

103. (previously presented) A method as in any of claim 102, wherein the at least one subsequent rate begins within a time period of 1 day to 12 weeks in a vascular environment.

104. (previously presented) A method as in any of claim 102, wherein the at least one subsequent rate begins within a time period of 2 days to 8 weeks in a vascular environment.

105. (previously presented) A method as in claim 102, wherein the at least one subsequent rate begins within a time period of 3 days to 50 days in a vascular environment.

106. (currently amended) A method as in claim ~~any of claims~~ 78, further comprising directing energy at the prosthesis to effect release of the substance from the prosthesis.

107. (previously presented) A method as in claim 78, wherein the prosthesis incorporates the substance by coating, spraying, dipping, deposition, or painting the substance on the prosthesis.

108. (previously presented) A method as in claim 78, wherein the substance is incorporated in a reservoir in or on a scaffold containing the substance.

109. (previously presented) A method as in claim 106, wherein the energy is at least one of ultrasound, magnetic resonance imaging, magnetic field, radio frequency, temperature change, electromagnetic, x-ray, radiation, heat, gamma, or microwave.

110. (currently amended) A method as in claim 78, wherein ~~78wherein~~ the prosthesis incorporates magnetic particles coupled to the substance and further comprising the step of directing a magnetic field at the prosthesis to effect release of the substance from the prosthesis.

111. (currently amended) A method as in any one of Claims 78-79, wherein the substance comprises at least one agent selected from the group consisting of immunosuppressant agent, anti-inflammatory agent, anti-proliferative agent, anti-migratory agent, anti-fibrotic agent, anti-thrombotic agent, anti-platelet agent, and IIb/IIIa agent.

112. (new) A method as in claim 78, wherein the initial rate is in a range between 0 μg/day to 50 μg/day.

113. (new) A method as in claim 112, wherein the initial rate is in a range between 5 μg/day to 30 μg/day.

114. (new) A method as in claim 78, wherein the at least one subsequent rate is in a range between 5 μg/day to 200 μg/day.

115. (new) A method as in claim 114, wherein the at least one subsequent rate is in a range between 10 μg/day to 100 μg/day.